Across TCGA pan-cancer cohorts, RNU6-869P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RNU6-869P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNU6-869P RNA is repressed in tumor relative to normal tissue. In most cancer types RNU6-869P is over-expressed in tumor, although a few such as KIRC and BRCA show the opposite, repressed pattern.

KIRC, BRCA, and LUSC are the cancer types where RNU6-869P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-869P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	−0.140	.002	7	view →
BRCA	All	II,III,IV	−0.333	<.001	6	view →
LUSC	Male	II,III,IV	−0.217	.033	2	view →
KICH	All	IV	−0.612	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RNU6-869P RNA expression & survival · all RNU6-869P data types